Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

The Effect Of Oral Ibandronate In Male Osteoporosis

ClinicalTrials.gov ID: NCT00397839

Public ClinicalTrials.gov record NCT00397839. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Parallel, Placebo-controlled, Randomized (2:1) Double-blind Study of One Year Duration to Assess the Effect of Oral Ibandronate 150 mg Given Once-monthly Versus Placebo on LS BMD in Men With Osteoporosis

Study identification

NCT ID
NCT00397839
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Hoffmann-La Roche
Industry
Enrollment
135 participants

Conditions and interventions

Interventions

  • Ibandronate Drug
  • placebo Drug

Drug

Eligibility (public fields only)

Age range
30 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2006
Primary completion
Sep 30, 2008
Completion
Sep 30, 2008
Last update posted
Dec 20, 2009

2007 – 2008

United States locations

U.S. sites
41
U.S. states
26
U.S. cities
39
Facility City State ZIP Site status
GSK Investigational Site Birmingham Alabama 35294-3708
GSK Investigational Site Tucson Arizona 85704
GSK Investigational Site Beverly Hills California 90211
GSK Investigational Site Greenbrae California 94904
GSK Investigational Site Oakland California 94609
GSK Investigational Site Palm Desert California 92260
GSK Investigational Site Walnut Creek California 94598
GSK Investigational Site Longmont Colorado 80501
GSK Investigational Site Clearwater Florida 33761
GSK Investigational Site Miami Florida 33136
GSK Investigational Site Miami Florida 33156
GSK Investigational Site Palm Harbor Florida 34684
GSK Investigational Site West Palm Beach Florida 33409
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Decatur Georgia 30033
GSK Investigational Site Gainsville Georgia 30501
GSK Investigational Site Champaign Illinois 61822
GSK Investigational Site Chicago Illinois 60611
GSK Investigational Site Peoria Illinois 61615
GSK Investigational Site Indianapolis Indiana 46250
GSK Investigational Site Kansas City Kansas 66160-7820
GSK Investigational Site Louisville Kentucky 40202
GSK Investigational Site South Portland Maine 04106
GSK Investigational Site Bathesda Maryland 20817
GSK Investigational Site Wheaton Maryland 20902
GSK Investigational Site Woodbury Minnesota 55125
GSK Investigational Site Springfield Missouri 65807
GSK Investigational Site Albuquerque New Mexico 87106
GSK Investigational Site Asheville North Carolina 28801
GSK Investigational Site Tulsa Oklahoma 74104
GSK Investigational Site Portland Oregon 97201
GSK Investigational Site Duncansville Pennsylvania 16635
GSK Investigational Site Providence Rhode Island 02908
GSK Investigational Site Charleston South Carolina 29407
GSK Investigational Site Dallas Texas 75216
GSK Investigational Site Richmond Virginia 23249
GSK Investigational Site Salem Virginia 24153
GSK Investigational Site Seattle Washington 98108
GSK Investigational Site Seattle Washington 98144
GSK Investigational Site Beckley West Virginia 25801
GSK Investigational Site Madison Wisconsin 53705

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00397839, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 20, 2009 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00397839 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →